Discover Diagnostic Laboratory, LLC

Discover Diagnostic Laboratory, LLC was paid $4.65M by Medicaid between Jan 2018 and Nov 2024, across 35 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 10% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	85,644	$775K
2019	75,005	$1.02M
2020	33,757	$727K
2021	31,471	$733K
2022	16,523	$380K
2023	18,993	$501K
2024incomplete	18,554	$521K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	10%	15,805	12,037	$483K
80356		6.0%	11,422	9,415	$281K
80361		5.7%	11,508	9,501	$264K
80346		4.8%	11,425	9,423	$225K
80348		4.6%	11,484	9,484	$214K
80354		4.4%	11,468	9,470	$204K
80358		4.3%	11,462	9,463	$201K
80345		4.2%	10,736	8,809	$198K
80363		4.1%	11,440	9,442	$190K
80365		3.9%	11,393	9,400	$183K
80332		3.9%	10,008	8,245	$181K
80336		3.9%	9,979	8,221	$180K

23 more codes

80353		3.6%	11,320	$168K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	3.4%	8,231	$159K
80373		3.4%	11,332	$157K
80349		3.3%	10,964	$152K
80359		3.2%	11,286	$149K
80372		3.2%	11,313	$149K
80360		3.1%	11,067	$145K
80355		2.7%	10,282	$126K
80370		2.6%	10,122	$120K
80367		2.3%	11,203	$106K
83992		2.2%	11,288	$101K
80366		2.1%	10,198	$96K
80325		2.0%	4,588	$93K
80324		1.6%	6,490	$77K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.0%	1,202	$48K
80369		<1%	80	$2K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	217	$1K
80323		<1%	47	$1K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	284	$969.04
80368		<1%	47	$482.16
80338		<1%	38	$379.99
80321		<1%	180	$340.25
80350		<1%	38	$298.48

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCOFFMAN, JOHN (CEO)